176 related articles for article (PubMed ID: 2459516)
1. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade.
van der Starre PJ; Reneman RS
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S54-61. PubMed ID: 2459516
[TBL] [Abstract][Full Text] [Related]
2. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
Cohen ML; Schenck KW; Kurz KD
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
Persson B; Gradin K; Pettersson A; Hedner T
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S22-4. PubMed ID: 2459509
[TBL] [Abstract][Full Text] [Related]
4. Are there interactions between S2-serotonergic and alpha 1-adrenergic receptors in isolated canine arteries?
Lüscher TF; Vanhoutte PM
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S16-21. PubMed ID: 2459508
[TBL] [Abstract][Full Text] [Related]
5. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
Hosie J; Stott DJ; Robertson JI; Ball SG
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
[TBL] [Abstract][Full Text] [Related]
6. Differences in vasodilating action between ketanserin, a 5-HT2-serotonergic receptor antagonist, and terazosin, an alpha 1-adrenoceptor antagonist, in anesthetized rabbits.
Ikeda K; Takata M; Tomoda F; Mikawa M; Iida H; Sasayama S
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S69-72. PubMed ID: 2446076
[TBL] [Abstract][Full Text] [Related]
7. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
[TBL] [Abstract][Full Text] [Related]
8. Alpha-adrenergic and serotonergic mechanisms in the human digit.
Coffman JD; Cohen RA
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S49-53. PubMed ID: 2459515
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive properties of ketanserin (R 41 468).
Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
[TBL] [Abstract][Full Text] [Related]
10. Comparison between ketanserin and LY 53857 on vascular and cardiac 5-HT2 and alpha 1-adrenergic receptors in the pithed rat.
Dabiré H; Chaouche-Teyara K; Cherqui C; Fournier B; Schmitt H
Arch Int Pharmacodyn Ther; 1990; 306():57-64. PubMed ID: 1981667
[TBL] [Abstract][Full Text] [Related]
11. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
Brouwer RM; Wenting GJ; Man in't Veld AJ; Schalekamp MA
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S26-31. PubMed ID: 2446064
[TBL] [Abstract][Full Text] [Related]
12. Interaction between S2-serotonergic and alpha 1-adrenergic receptor activities at vascular sites.
Van Nueten JM; Janssens WJ; Xhonneux R; Janssen PA
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S10-5. PubMed ID: 2459506
[TBL] [Abstract][Full Text] [Related]
13. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
[TBL] [Abstract][Full Text] [Related]
14. Ketanserin: haemodynamic effects and mechanism of action.
Schalekamp MA; Woittiez AJ; Wenting GJ; van den Meiracker AH; Man in 't Veld AJ
J Hypertens Suppl; 1986 Apr; 4(1):S7-12. PubMed ID: 2871144
[TBL] [Abstract][Full Text] [Related]
15. Potential vascular alpha1-adrenoceptor blocking properties of an array of 5-HT receptor ligands in the rat.
Centurión D; Mehotra S; Sánchez-López A; Gupta S; MaassenVanDenBrink A; Villalón CM
Eur J Pharmacol; 2006 Mar; 535(1-3):234-42. PubMed ID: 16545797
[TBL] [Abstract][Full Text] [Related]
16. An investigation of the effects of intravenous injection of the 5-hydroxytryptamine 2 receptor antagonists ketanserin and LY 53857 on blood pressure in anesthetized spontaneously hypertensive rats.
Docherty JR
J Pharmacol Exp Ther; 1989 Feb; 248(2):736-40. PubMed ID: 2537414
[TBL] [Abstract][Full Text] [Related]
17. Effects of antagonists of 5-hydroxytryptamine on blood pressure in the anesthetised spontaneously hypertensive rat.
Docherty JR; Warnock P
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S59-61. PubMed ID: 2446073
[TBL] [Abstract][Full Text] [Related]
18. Evidence for an alpha-1 receptor-mediated central sympathoinhibitory action of ketanserin.
McCall RB; Schuette MR
J Pharmacol Exp Ther; 1984 Mar; 228(3):704-10. PubMed ID: 6323678
[TBL] [Abstract][Full Text] [Related]
19. Antagonism by methysergide of neurogenic vasoconstriction in the dog forelimb.
Jandhyala BS; Kivlighn SD
Fed Proc; 1987 Feb; 46(2):276-80. PubMed ID: 3100343
[TBL] [Abstract][Full Text] [Related]
20. Contractions of isolated canine coronary arteries resistant to S2-serotonergic blockade.
Cohen RA
J Pharmacol Exp Ther; 1986 May; 237(2):548-52. PubMed ID: 2939235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
